214147-60-1

Usage

Uses

Used in Pharmaceutical Industry:
2-Chloro-benzoiMidazole-1-carboxylic acid tert-butyl ester is used as a key intermediate for the synthesis of various pharmaceutical compounds. Its presence in the benzimidazole class suggests potential applications in the development of drugs with diverse therapeutic effects, given the class's known biological activities.
Used in Chemical Synthesis:
In the field of chemistry, 2-Chloro-benzoiMidazole-1-carboxylic acid tert-butyl ester is utilized as an important building block for the creation of other complex molecules. Its structure, which includes a chlorine atom and a tert-butyl ester, provides a versatile platform for further chemical reactions and modifications, facilitating the synthesis of a wide range of chemical products.
Used in Research and Development:
2-Chloro-benzoiMidazole-1-carboxylic acid tert-butyl ester is employed as a research compound in academic and industrial laboratories. Its detailed properties and reactivity are studied to understand its potential applications and to develop new methodologies for its synthesis and use in various chemical processes.

Upstream product

• 4857-06-1 2-chloro-1H-benzoimidazole 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 851597-50-7 2-(2-methoxy-phenoxy)-1H-benzoimidazole 
• 851597-48-3 2-(2,6-dimethyl-phenoxy)-1H-benzoimidazole 
• 256527-06-7 tert-butyl 2-[(2S)-2-[(benzyloxy)carbonyl]-1-piperidinyl]-1H-1,3-benzimidazole-1-carboxylate 

Relevant academic research and scientific papers

TETRAHYDROISOQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF

Provided are a tetrahydroisoquinoline derivative, a preparation method therefor and an application thereof in medicine. In particular, provided are a tetrahydroisoquinoline derivative represented by general formula (I), a preparation method therefor and a

Synthesis of 4-((1H-benzo[d]imidazol-2-yl)oxy)-3-methylpicolinic acid, a key related substance of Rabeprazole sodium

4-((1H-benzo[d]imidazol-2-yl)oxy)-3-methylpicolinic acid (11) is a key related substance of Rabeprazole sodium. In this article, this key related substance is synthesized by using 3-methylpicolinonitrile as a starting material via a five-step processes. By converting 3-methylpicolinonitrile to 4-hydroxy-3-methylpicolinonitrile (13), the preparation of TM becomes practical. This work provides a guarantee for quality standard establishment of Rabeprazole sodium.

Light Induced C-C Coupling of 2-Chlorobenzazoles with Carbamates, Alcohols, and Ethers

A light induced, transition-metal-free C-C coupling reaction of 2-chlorobenzazoles with aliphatic carbamates, alcohols, and ethers is presented. Inexpensive reagents, namely sodium acetate, benzophenone, water, and acetonitrile, are employed in a simple reaction protocol using a cheap and widely available 25 W energy saving UV-A lamp at ambient temperature.

Design, syntheses, and structure-activity relationships of novel NPY Y5 receptor antagonists: 2-{3-Oxospiro[isobenzofuran-1(3H),4′-piperidin]-1′-yl}benzimidazole derivatives

Design, syntheses, and structure-activity relationships of a novel class of 2-{3-oxospiro[isobenzofuran-1(3H),4′-piperidin]-1′-yl}benzimidazole NPY Y5 receptor antagonists are described. The benzimidazole structures were newly designed based on the urea linkage of our prototype Y5 receptor antagonists (2 and 3). By optimizing substituents on the benzimidazole core part of the lead compound 5a, we were able to develop a potent, orally available, and brain-penetrable Y5 selective antagonist (5k). Crown Copyright

SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE

The present invention relates to hydroxybenzimidazole pyrimidines or pyridines or pharmaceutically-acceptable salts thereof. Also included is a method of treatment of inflammation, inhibition of T cell activation and proliferation, arthritis, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, organ transplant, acute transplant or heterograft or homograft rejection, transplantation tolerance induction, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, including ulcerative colitis, Crohn's disease, lupus, contact hypersensitivity, delayed-type hypersensitivity, and gluten-sensitive enteropathy, type 1 diabetes, psoriasis, contact dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune polyglandular disease, autoimmune alopecia, pernicious anemia, vitiligo, autoimmune hypopituatarism, Guillain-Barre syndrome, glomerulonephritis, serum sickness, uticaria, allergic diseases, asthma, hayfever, allergic rhinitis, scleracielma, mycosis fungoides, dermatomyositis, alopecia areata, chronic actinic dermatitis, eczema, Behcet's disease, Pustulosis palmoplanteris, Pyoderma gangrenum, Sezary's syndrome, atopic dermatitis, systemic schlerosis, morphea, atopic dermatitis, colon carcinoma or thymoma in a mammal comprising administering a therapeutically-effective amount a compound as described above.

Pharmaceutical composition for the treatment of CNS and other disorders

The present invention relates to a method of treating disorders of the Central Nervous System (CNS) and other disorders in a mammal, including a human, by administering to the mammal a CNS-penetrant α7 nicotinic receptor agonist. It also relates to pharma

Pharmaceutical compositions for CNS and other disorders

The present invention relates to a method of treating disorders of the Central Nervous System (CNS) and other disorders in a mammal, including a human, by administering to the mammal a CNS-penetrant α7 nicotinic receptor agonist. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier and a CNS-penetrant α7 nicotinic receptor agonist.

Heterocyclic compounds as inhibitors of rotamase enzymes

Compounds of the formula (I): wherein A, Y, R, X, R1, R2, R3and R4are as defined above are inhibitors of rotamase enzymes in particular FKBP-12 and FKBP-52. The compounds therefore moderate neuronal regeneration and outgrowth and can be used for treating neurological disorders arising from neurodegenerative diseases or other disorders involving nerve damage.

FKBP inhibitors

Compounds of formula (I), their salts and solvates, wherein the substituents are as described herein, are FKBP inhibitors.